van der Leest, Rozendal et al. identify therapeutically relevant mutations in circulating tumor DNA profiles at baseline for patients with non-small cell lung cancer. They detect more circulating tumor DNA mutations using both plasma and tumor tissue compared to tissue detection of mutations alone.
- Paul van der Leest
- Pim Rozendal
- Ed Schuuring
